Long-term Safety of Tozorakimab in COPD Patients
Part of Lungs & breathing clinical trials.
This study follows patients who previously took part in a tozorakimab trial to see how safe the drug is over time. Tozorakimab is an antibody treatment designed to reduce flare-ups (exacerbations) in people with COPD, a chronic lung disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have participated in an earlier tozorakimab study for COPD
- You live in France and are enrolled in French Social Security
- You are willing and able to use contraception as previously agreed
- You have COPD as your main lung condition (no other serious lung diseases)
- You have not received recent immunosuppressive medications or live vaccines (within specific timeframes)
- You are able to follow all study visits, procedures, and restrictions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called tozorakimab for adults whose asthma is not well controlled despite using medium-to-high dose inhaled steroids. The study aims to find the best dose and see if it reduces asthma attacks.
This Phase 3 study tests tozorakimab to see if it helps people hospitalized with a viral lung infection that is causing low oxygen levels. You might qualify if you still need supplemental oxygen when the study starts.
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.